Technical Analysis for BDSX - Biodesix, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Fell Below 20 DMA | Bearish | 0.00% | |
| Fell Below 200 DMA | Bearish | 0.00% | |
| MACD Bearish Signal Line Cross | Bearish | 0.00% | |
| 180 Bearish Setup | Bearish Swing Setup | 0.00% | |
| Expansion Breakdown | Bearish Swing Setup | 0.00% | |
| Volume Surge | Other | 0.00% | |
| Wide Range Bar | Range Expansion | 0.00% | |
| Earnings Movers | Other | 0.00% | |
| BB Squeeze Ended | Range Expansion | 0.00% | |
| Below Lower BB | Weakness | 0.00% |
| Alert | Time |
|---|---|
| 60 Minute Opening Range Breakdown | about 19 hours ago |
| 2x Volume Pace | about 23 hours ago |
| 1.5x Volume Pace | about 23 hours ago |
| Gapped Down (Full) | about 23 hours ago |
| 200 DMA Resistance | about 23 hours ago |
Free Daily (Stock) Chart Reading
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 11/01/2024
Biodesix, Inc. operates a data-driven diagnostic solutions company in the United States. The company offers blood-based tests across the lung cancer continuum of care, such as Nodify XL2 and Nodify CDT tests to help physicians reclassify risk of malignancy in patients with suspicious lung nodules; and GeneStrat tumor profiling and VeriStrat immune profiling tests provide physicians with timely results to facilitate treatment decisions. It also offers include diagnostic research, clinical research, development, and testing services to biopharmaceutical companies, as well as develops and commercializes companion diagnostics. The company was formerly known as Elston Technologies, Inc. Biodesix, Inc. was incorporated 2005 and is headquartered in Boulder, Colorado.
Sector: Healthcare
Industry: Diagnostics & Research
Keywords: Biopharmaceutical Clinical Research Lung Cancer Companion Diagnostic Diagnostic Solutions
Classification
Sector: Healthcare
Industry: Diagnostics & Research
Keywords: Biopharmaceutical Clinical Research Lung Cancer Companion Diagnostic Diagnostic Solutions
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 2.21 |
| 52 Week Low | 1.15 |
| Average Volume | 184,217 |
| 200-Day Moving Average | 1.60 |
| 50-Day Moving Average | 1.72 |
| 20-Day Moving Average | 1.62 |
| 10-Day Moving Average | 1.60 |
| Average True Range | 0.10 |
| RSI (14) | 27.54 |
| ADX | 21.86 |
| +DI | 13.32 |
| -DI | 34.30 |
| Chandelier Exit (Long, 3 ATRs) | 1.45 |
| Chandelier Exit (Short, 3 ATRs) | 1.58 |
| Upper Bollinger Bands | 1.79 |
| Lower Bollinger Band | 1.46 |
| Percent B (%b) | -0.48 |
| BandWidth | 20.33 |
| MACD Line | -0.04 |
| MACD Signal Line | -0.03 |
| MACD Histogram | -0.0128 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 1.89 | ||||
| Resistance 3 (R3) | 1.94 | 1.81 | 1.79 | ||
| Resistance 2 (R2) | 1.81 | 1.66 | 1.78 | 1.75 | |
| Resistance 1 (R1) | 1.55 | 1.57 | 1.49 | 1.50 | 1.72 |
| Pivot Point | 1.42 | 1.42 | 1.38 | 1.39 | 1.42 |
| Support 1 (S1) | 1.16 | 1.27 | 1.10 | 1.11 | 0.88 |
| Support 2 (S2) | 1.03 | 1.18 | 1.00 | 0.85 | |
| Support 3 (S3) | 0.77 | 1.03 | 0.81 | ||
| Support 4 (S4) | 0.72 |
